



**World TB Day
Symposium
2024**

Delegate Information

Thank you for joining us for our World TB Day Symposium. We hope that you will find the day very worthwhile. Below is information for the day; if you have any queries please seek out a member of the volunteer team (wearing [a light blue lanyard](#)).

Breaks: Refreshments will be available from two tables on each floor—please make use of them all! All food is vegetarian; vegan and special diets: please collect from Registration desk. Toilets are on the far side of the foyers on each floor (street level—across the bridge). We will start promptly after breaks—please leave time to get back to your seats.

Sponsors: This symposium has always been free to attend, and that's the case again this year. This is possible because of the involvement of our sponsors, who are all companies and organizations involved in the control of TB and other mycobacterial infections. We are grateful for their support. Read more about them on pp 14-15, and visit them at their stands at street level.

Coats and bags: There is a coat rail near the building entrance, and an unstaffed cloakroom is available on the far left of the lower ground floor. You use these at your own risk, and we cannot accept any responsibility for belongings that go missing.

Accessibility: Wheelchair access to the Kennedy Lecture Theatre is via lift to the lower ground floor, entering the theatre at the front.

Filming and photography: The talks in the Kennedy Lecture Theatre are being filmed. There will also be a photographer present from ~1445-1545 in the afternoon (i.e. during the afternoon sessions and tea break), and this content may be used for publicity and promotional purposes, and may appear online and/or in printed material. If you do not wish to be included, please notify the photographer or organiser as soon as possible who will provide you with [a red lanyard](#) to ensure your privacy is protected.


Fire safety: In the unlikely event of a fire alarm, please follow instructions given by the fire marshals. You will be directed to exit either via the main entrance or through the door to the right of the Kennedy Lecture Theatre stage, whichever is nearer.

From the UCL and LSHTM World TB Day Team

Using Zoom chat: If you would like to be involved with the online chat, log in to the webinar <https://ucl.zoom.us/j/99899647629>



Wifi: Eduroam wifi is available; alternatively people can log into **UCL Guest** wifi, which is based on logging into, or registering at Sky Wifi (The Cloud). More information at <https://www.ucl.ac.uk/isd/how-to/connecting-to-uclguest-wi-fi-cloud>



Debate: For our debate, we will be having a vote before and after using Mentimeter.

Join using your phone: Go to [menti.com](https://www.menti.com), and use code **4369 5228**, or use the QR code on the right. You will only be able to vote once on each occasion.



Thanks and acknowledgements:

The programme of talks was devised by a group from UCL and LSHTM, led by Gabriele Pollara: Frank Klopogge, Emily Shaw, Annabelle South (UCL) and Sian Floyd, Palwasha Khan, Katherine Horton, Rein Houben and Esin Nkereuwem (LSHTM)

The events delivery team were: Neil Stoker and Christiana Oyefolu with support from Patrycja Kaca and Anna Shepherd, and the UCL-TB Delivery Group, and Hanh Gurr managed the financial side.

We thank people who volunteered from both institutions to help on the day; all at ICH, including the porters, cleaners, caterers and reception staff; the audiovisual, photography and video staff; all the speakers and those chairing sessions; and all the others who have supported us in putting on this event. The image on the cover is used courtesy of Mishal Khan.

Programme

09:00 Welcome and Introductory Remarks

Marc Lipman (Director, UCL-TB) & **Sedona Sweeney** (Co-director, LSHTM TB Centre)

Shabbar Jaffar (Director, UCL Institute for Global Health)

Liam Smeeth (Director, LSHTM)

Lele Rangaka (Director, UCL-WHO Collaborating Centre for Tuberculosis Research and Innovation)

09:20 Global TB advocacy post-UN-HLM 2023: A political perspective

Lord Herbert (co-chair, Global TB Caucus)

Eliud Wandwalo (Head of TB, The Global Fund to Fight AIDS, TB and Malaria) *Investing to end TB: Opportunities and challenges*

09:35 Session 1: Inclusivity and accessibility

Chairs: **Jess Potter**; **Al Story** (UCL)

Samara Barnes (Affected Community co-lead, UKAPT) *First-hand experience of TB care*

Kate Yorke (Inclusion Health Division, UKHSA) *TB in asylum seekers*

Lena Faust (LSHTM/McGill/Universidad Peruana Cayetano Heredia) *TB in Peruvian prisons*

Limakatso Lebina (AHRI) *Accessibility of novel TB treatments in a high burden country*

Panel discussion and Q&A

10:35 Break & refreshments (foyer both levels)

11:10 Session 2: Social and structural determinants

Chairs: **Katherine Horton**; **Palwasha Khan** (LSHTM)

Julia Pescarini (LSHTM) *Studying social protection using linked data: how housing, cash and access to primary healthcare can improve TB in Brazil*

Chukwuebuka Ugwu (Zankli Research Centre) *Addressing men's barriers to TB diagnosis and care in peri-urban settlements in Nigeria*

Finn McQuaid (LSHTM) *Modelling the epidemiological impact of a nutritional intervention for TB-affected households*

Delia Boccia (WHO/LSHTM) *Social protection and TB: what else do we need to know?*

Panel discussion and Q&A

12:10 Debate: This House believes that the current END TB targets should be revised

Chair: **Helen Stagg** (LSHTM)

Speaking for: **Richard White** (LSHTM)

Speaking against: **Suvanand Sahu** (Deputy Director Stop TB Partnership)

13:00 Lunch break (*foyer both levels*)

14:00 Session 3: New therapeutic approaches

Chairs: **Tine Arnvig** (UCL); **Hazel Dockrell** (LSHTM)

Al Leslie (UCL/AHRI) *Do fibroblasts shape the TB granuloma?*

Gillian Tomlinson (UCL) *Contribution of type I interferon responses to immune protection against mycobacterial infection*

Linzy Elton (UCL) *The role of BCG strains in TB vaccine development*

Rebecca Clark (LSHTM) *Modelling the health and economic impacts of varying delivery strategies for TB vaccines*

Panel discussion and Q&A

15:00 Break (*foyer both levels*)

1530 Session 4: Clinical trials: From design through to policy

Chairs: **Ruth Goodall** (UCL); **Daniel Grint** (LSHTM)

Hanif Esmail (UCL) *Evaluating the pipeline of new drugs: The design of the PARADIGM4TB trial*

Helen Ayles (LSHTM) *The TREATS trial, its implementation and implications of its findings*

Chishala Chabala (LSHTM & UTH, Zambia) *Implementing the results of the SHINE trial*

Panel discussion and Q&A

16:30 UCSF Link up

Sophie Huddart (UCSF) on their symposium held on Friday 22nd

16:40 Summary and close

Gabriele Pollara (UCL)

16:50-19:00 Drinks reception (*Lower ground floor*)

Speaker Biographies

Welcome

Marc Lipman

Professor of Respiratory Medicine, UCL

Marc is Director of UCL-TB and Honorary Consultant in Respiratory and HIV Medicine at the Royal Free Hospital, where he leads the mycobacterial clinical service. He chairs the UK Joint TB Committee, and NTM Network UK, the country's largest Non-Tuberculous Mycobacteria clinical research group. He is UKAPTb's Executive Committee Clinical Lead; and sits on international and national guideline groups for TB and HIV-related respiratory infection. His research focuses on improving patient outcomes and healthcare delivery.

Sedona Sweeney @SedonaSweeney

Assistant Professor in Health Economics, LSHTM

Sedona is a health economist, with a research focus on the economic impact of substantial long-term health shocks, both at the provider level and within the household. She has a particular interest in measurement and understanding of the costs of chronic illness – including HIV, TB, chronic non-communicable diseases, and HCV. She is co-Director for the LSHTM TB Centre.

Shabbar Jaffar

Director, UCL Institute for Global Health

Shabbar is an epidemiologist and a clinical trialist, previously at the Liverpool School of Tropical Medicine for a Professor of Epidemiology at LSHTM. His research interests are in high burden disease conditions in sub-Saharan Africa.

Liam Smeeth @LiamSmeeth1

Director, LSHTM

Liam is Professor of Clinical Epidemiology, and also a clinician in NHS general practice. His broad research interests include disease aetiology, drug effects, genetics, health and climate change, and non-communicable diseases in low income settings.

Lele Rangaka @LeleRangaka

Professor of Infectious Disease Epidemiology & Public Health, UCL; honorary Associate Professor, University of Cape Town

Lele is an Infectious Disease Clinical Scientist with over 15 years experience, her research areas span HIV/TB epidemiology, randomized assessments of public health technology, digital health innovation and implementation science. She conducts clinical trials of TB prevention focusing on integrating

biomedical and non-biomedical strategies across multimorbidities, innovation in adherence monitoring, diagnostics and m-health. She is director of the WHO Collaborating Centre for Tuberculosis Research and Innovation, and co-UCL lead of the TB-IPD platform

Global TB advocacy

Lord Herbert @nickherbertcbe

Nick Herbert — Lord Herbert of South Downs — has championed TB for nearly two decades. As a newly elected MP he helped to form the All Party Parliamentary Group on Global TB which he continues to co-chair as a Member of the House of Lords. He also chairs the Global TB Caucus which he launched in 2014, initiating the Barcelona Declaration with a speech to the World Lung Conference.

Eliud Wandwalo

Head of TB, The Global Fund to Fight AIDS, TB and Malaria

Eliud joined the Global Fund in 2013. As the Head of TB, he serves as the primary point for leadership and strategic guidance on TB, collaborating across the Global Fund secretariat and external partners to ensure Global Fund resources are strategically invested for impact. Before joining the Global Fund, Eliud worked with Management Sciences for Health, and for the National TB Programme in Tanzania. He studied medicine at the University of Dar Es Salaam, has a PhD from Bergen University.

Session 1

Jess Potter @DrJessPotter

Consultant in Respiratory Medicine, North Middlesex University Hospital

Jess is a respiratory physician and lead of the TB service at a busy hospital in North London. She is an honorary senior clinical lecturer at UCL with a background in critical public health and qualitative research methods focusing on healthcare access, migration, and TB. Jess has been involved with a range of advocacy organisations and currently co-chairs the network UK Academics & Professionals to End TB and is part of the Innovations Constituency of the Stop TB partnership.

AI Story

UCL Professor of Inclusion Health and Founder and Clinical Lead of the London Find&Treat Service

His work focusses on equity and strengthening TB and Blood-Borne Virus control through integrated outreach models, screening and point-of-care diagnostics, peer-led community interventions, and using mobile digital technologies to promote engagement and treatment continuity. He is Co-director of the UCL Collaborative Centre for Inclusion Health.

Samara Barnes @SamaraBarnes1

UKAPT B Affected Communities Co-Lead

Samara is the Affected Communities Co-Lead for UKAPT B. She was diagnosed with active pulmonary TB in late 2015 which was later found to be drug resistant. Samara is a local and county councillor, she has raised money for TB Alert and has been part of their peer supporter programme too. Recently, Samara has spoken about 'the patients perspective' with the UK Health Security Agency and recorded a piece for National Prison Radio highlighting the signs, symptoms and the importance of early diagnosis for TB.

Kate Yorke

Consultant in Public Health

Kate leads the refugee and asylum seeker portfolio for the Inclusion Health team at the UK Health Security Agency. She works across government and with academic, voluntary and community sector partners to improve health outcomes for people affected by extreme health inequities. Her priority areas include improving the information captured on inclusion health populations in infectious disease surveillance systems, increasing the evidence base on the impact of infectious diseases and effective models of interventions, and development of national guidance.

Lena Faust @LenaFaust1

Visiting Postdoctoral Fellow, LSHTM

Lena recently completed her PhD in Epidemiology at McGill University and the McGill International TB Centre in Montréal, Canada, and is now a Post-doctoral Fellow at LSHTM, co-supervised by César Ugarte-Gil (UPCH, UTMB) and David Moore (LSHTM), focusing her postdoctoral research on TB in prisons in Peru. She is also contributing to ongoing projects to understand global trends in TB in prisons more broadly and highlight data gaps in this area. As part of the Steering Committee of the Stop TB Canada Network, Lena is also involved in TB advocacy.

Limakatso Lebina @LimakatsoLebina

Director for Clinical Trials, Africa Health Research Institute

Limakatso is a clinician and an experienced researcher, who has managed multiple clinical trials and implementation science research studies on HIV, TB, and COVID-19 prevention and treatment. Her current research includes improving diagnosis for TB in people accessing primary healthcare services, TB vaccines and new HIV regimens clinical trials. Limakatso is a member of the South African TB THINK Tank and was involved in writing TB screening guidelines. She is also one of South African representative to the BRICS TB Research Network.

Session 2

Katherine Horton @kc_horton

Assistant Professor, Department of Infectious Disease Epidemiology, LSHTM

Katherine is an infectious disease epidemiologist with interests in understanding and addressing gaps in access to TB prevention and care. Her current research focuses on social determinants, particularly gender inequities, and the impact of the spectrum of TB disease.

Palwasha Khan @dopapus

Associate Professor in Infectious Disease Epidemiology, LSHTM; Honorary Consultant in HIV medicine, Cardiff

Palwasha's research interests include understanding population-level drivers of *M. tuberculosis* transmission in different epidemiological contexts and characterising the role of socio-biological mechanisms that are driving disparities in exposure and susceptibility to *M. tuberculosis* which leads to the differential distribution of tuberculosis observed in populations.

Julia Pescarini

Assistant Professor, Faculty of Epidemiology and Population Health, LSHTM; The Centre for Data and Knowledge Integration for Health (CIDACS), Oswaldo Cruz Foundation from Brazil

Julia is a social epidemiologist with a research focused on understanding the links between social and environmental drivers of disease of poverty; as well as understanding how global health challenges can disproportionately affect people from racial, ethnic and socioeconomic minorities, such as migrants. She has a special interest in applying robust methods to understand causal associations and conduct policy evaluations that can be used to advocate for changes.

Chukwuebuka Ugwu @MaziChukwuebuk1

Early Career Researcher, Liverpool School of Tropical Medicine based at Zankli Research Centre, Nigeria

Ebuka is a medical doctor with experience in implementing public health interventions and designing disease surveillance systems for communicable diseases in Nigeria. He has particular interest in leveraging the experiences of stakeholders in co-creating solutions for disease control challenges within disadvantaged urban communities. His PhD research, as part of the LIGHT consortium, is developing community-led gender-responsive approaches that will enable better care access for people with TB in peri-urban settlements in Nigeria.

Finn McQuaid @CFMcQuaid

Associate Professor, LSHTM

Finn is a TB modeller and the TB Modelling and Analysis Consortium (TB

MAC) Secretariat Epidemiologist, involved in developing guidance and resources for country-level TB modelling to support decision-making, and facilitating coordination between international funders and stakeholders. His research focuses on TB treatment and care, including drug-resistance, as well as the impact of crises on TB.

Delia Boccia @leonedelia

Delia is a leading expert on the social epidemiology of TB. She is currently acting as consultant for the Global Tuberculosis Programme of the World Health Organization to support the consolidation and implementation of its social protection policy agenda. Before this, she worked for 10 years as quantitative social epidemiologist for LSHTM. The evidence she generated during her academic career have contributed substantially to inform Pillar 2 of the WHO End TB strategy.

Debate

Helen Stagg @hr_stagg

Professor of Infectious Disease Epidemiology, LSHTM

Helen is an infectious disease epidemiologist with a particular interest in causal inference within observational studies. She runs a research programme in anti-tuberculosis treatment regimens and non-adherence. She is currently a formal advisor to WHO's Scientific Guidance on Evidence Generation on new regimens for tuberculosis treatment Development Group and a Core group member of the WHO European Tuberculosis Research Initiative.

Richard White @richardwhite321

Professor, Department of Infectious Disease Epidemiology, LSHTM

Richard is an infectious disease epidemiologist with 20+ years experience at global and country level. He is currently TB lead of Global Fund Modelling Guidance Committee, and member of the WHO Global Task Force on TB Impact Measurement Methods Committee. He has served as health impact lead of StopTB/WHO Global Plan Update Task Force, on South Africa government's TB Think Tank Expert Committee, co-chair for Global Burden of Disease Independent Committee on TB, and chaired the Research and Innovation Pillar on WHO STAG.

Suvanand Sahu @SahuSuvanand

Deputy Executive Director, Stop TB Partnership

Suvanand is a medical doctor and a trained public health specialist with over 18 years of experience in TB. He previously worked with WHO on TB in India, and on polio, HIV, and maternal and child health.

Session 3

Tine Arnvig @tarnvig

Associate Professor, Institute of Structural and Molecular Biology, UCL

Tine's research interests revolve around *M. tuberculosis* RNA biology from transcription initiation to termination of translation. Her lab uses a combination of high-throughput methods and classical genetics and molecular biology to investigate how transcriptional and post-transcriptional control facilitates *M. tuberculosis* pathogenesis and persistence.

Hazel Dockrell

Professor of Immunology, LSHTM

Hazel is an immunologist whose research focuses on the development of correlates of protection for tuberculosis, and the development of assays and biosignatures that could predict the development of TB, monitor TB therapy, or provide a triage test for TB.

Al Leslie

Professor, Africa Health Research Institute

Al is an immunologist interested in the immunopathology of TB and HIV. His group at AHRI studies the host-pathogen interactions that occur in tissue, particularly in the lung with TB. They make use of 3D-granuloma models to explore tissue-specific correlates of protective immunity and pathology, with the aim of identifying potential targets for host-directed therapies and biomarkers of disease progression.

Gillian Tomlinson @DrGTomlinson

Clinician Scientist, UCL

Gillian is a Clinician Scientist in the UCL Division of Infection and Immunity and an Honorary Consultant in Respiratory and General Medicine at University College London Hospital. Her research integrates a human experimental model to identify master regulators of immune responses that correlate with severity of tuberculosis, with genetic manipulation of zebrafish for mechanistic studies to test causality for observed associations. Ultimately, her work aims to drive innovation in tuberculosis treatment, vaccine development and diagnostic strategies.

Linzy Elton @LinzyElton

Postdoctoral Research Associate, Centre for Clinical Microbiology, UCL

Linzy mainly focuses on genomics, tuberculosis, antimicrobial resistance (AMR) and One Health. She recently developed a cost-effective multi-drug resistant TB sequencing pipeline for use in low- and middle-income countries and is currently developing a genomic AMR surveillance tool. Much of her work is focussed on capacity development in resource poor settings and she has a particular interest in creating open-access resources for early career researchers.

Rebecca Clark @ra_clark18

Research Fellow, TB Modelling Group, LSHTM

Rebecca is a research fellow in the TB Modelling Group at LSHTM. Her research is focussed on using mathematical modelling to evaluate the health and economic impacts of interventions to reduce the burden of tuberculosis worldwide, primarily of new vaccines and their interactions with social determinants.

Session 4

Ruth Goodall

Senior Statistician, MRC Clinical Trials Unit at UCL

Ruth has over 20 years of experience in infectious disease research. Initially focusing on HIV infection, she more recently joined the TB programme as a trial statistician for STREAM. Ruth is currently the co-lead for the WHO TB-IPD platform, a data curation project for TB treatment trials and observational datasets.

Daniel Grint @DanielJGrint

Associate Professor of Medical Statistics and Epidemiology, LSHTM

Daniel is a statistician and clinical trialist working in the International Statistics and Epidemiology Group at LSHTM. His research interests include randomised trials of novel treatments for both TB and HIV, observational studies of the accuracy of TB diagnostic tools and the effectiveness of TB preventative therapies, and methodological research focused on achieving efficiencies in the randomised trial framework for new TB treatment regimens

Hanif Esmail @hanifesmail_tb

Clinical Associate Professor in Infectious Diseases, UCL

Hanif has a joint position between the MRC CTU and the Institute for Global Health at UCL, as well as being an Honorary Consultant in Infectious Diseases and Tropical Medicine at University College London Hospitals. His research mainly focuses on optimal diagnostic and treatment approaches for early TB disease, and on pragmatic, person-centred management of drug resistant TB in decentralised settings

Helen Ayles @helen_ayles

Professor of Infectious Diseases and International Health, LSHTM; Director of Research Zambart, Zambia

Helen is a clinical epidemiologist who works predominantly on the combined challenges of TB and HIV. Her work includes testing new diagnostics and implementation research to try to end both epidemics. Helen has lived in Zambia for the past 26 years and leads research at Zambart, a multi-disciplinary research group affiliated with UNZA School of public health. She is a member of WHO TB-STAG and has served on several national and international TB and HIV committees.

Chishala Chabala @cchabala0407

Lecturer and Consultant Paediatrician, University of Zambia and University Teaching Hospital, Lusaka, Zambia

Chishala is a lecturer and consultant paediatrician at the University of Zambia, School of Medicine and the University Teaching Hospitals in Lusaka, Zambia. He also part-time faculty at LSHTM. He co-leads a research group focusing on clinical research on tuberculosis, HIV, and pneumonia in children and has been an investigator in several multinational collaborative clinical trials. He is the Vice-Chair of the Child and Adolescent Working Group of the WHO/STOP TB partnership and contributed to the guidelines' development group of the WHO.

UCSF Link up

Sophie Huddart @SKHuddart

Assistant Professor, University of California San Francisco

Sophie is a TB epidemiologist with a research interest in TB quality of care. In particular, Sophie researches post-TB outcomes and the utility of digital health tools to improve patient outcomes. Sophie is a member of the UCSF World TB Day organizing committee.

Summary and close

Gabriele Pollara @gpollara

Associate Professor in Infection at UCL and Honorary Consultant in Infectious Diseases at UCLH

Gabriele's research focuses on dissecting the pathophysiology of TB disease using systems-level bioinformatic deconvolution of bulk- and single cell-transcriptional responses from the sites of challenge models and disease, alongside spatial transcriptomic assessments, population-level genetic epidemiology and tractable in vitro models. His overarching goals are to define rational host-directed therapeutic targets to attenuate tissue pathology and improve post-TB lung disease.


Reception

Gloria Wu

Pianist

Gloria is studying for an MSc in psychology at UCL, having previously studied piano at the Royal Northern College of Music and obtained a Master of Performance degree. In addition to her academic studies, she is passionate about incorporating music into many different aspects of life to bring joy to others. Asked to play music from people whose lives were affected by TB, she is keen to perform pieces by Chopin in particular.

Our Sponsors



With over 20 years of experience in mycobacteria molecular diagnostics Bruker contributes to the fight against tuberculosis (TB), NTM and leprosy. We have a WHO recommended comprehensive portfolio with diagnostic tests focusing on resistance as well as rapid identification. Bruker's LiquidArray technology can provide identification of TB and simultaneous detection of 47 resistance mutations for first line treatment, XDR-TB detection and NTM speciation in under 3 hours.



Cepheid are a leading rapid molecular diagnostics company that is dedicated to improving healthcare by developing fully-integrated systems and accurate yet easy-to-use molecular tests. Cepheid is devoted to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility, focusing on fields such as critical and healthcare-associated infections, sexual health, genetic diseases, virology and cancer.



QIAGEN is the leading global provider of Sample to Insight solutions and have been supporting efforts to eradicate TB since 2011. The fourth generation of our assay; QuantiFERON-TB Gold Plus is the world's leading IGRA blood test, with millions of tests performed annually. It has benefited patients and providers by reducing the number of visits to a single blood draw with a faster turnaround time.



[Qure.ai](#) is a health tech company utilising deep learning and AI tools to make healthcare more accessible and affordable globally. Their technology, including qXR, addresses critical needs in the radiology industry, prioritising actionable patient cases and allowing radiologists to focus on the most pressing diagnoses.



Revvity is a pioneering force in health science solutions, offering end-to-end workflows from discovery to development and diagnosis to cure.

The T-SPOT.TB test is a T cell based IGRA that uses a simplified ELISPOT technology, for the detection of TB infection.

The T-SPOT.TB test is part of the Revvity portfolio and we are committed to joining the fight to end TB.



The Global Fund is a worldwide partnership to defeat HIV, TB and malaria and ensure a healthier, safer, more equitable future for all. The Global Fund provides 76% of all international financing for TB. In countries where the Global Fund invests, TB deaths have dropped by 36% between 2002 and 2022. Without these interventions, TB deaths would have increased by 129% in the same period.

OUTPATIE
Continuum



AHF

កម្ពុជា
វិទ្យាសាស្ត្រសុខាភិបាល

ស្ត្រីម្នាក់មានជំងឺស្រពិលស្រពិល

